COPPELL, Texas--(BUSINESS WIRE)--ZS Pharma, Inc., a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced the closing of its initial public offering of 6,836,111 shares of common stock at a public offering price of $18.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 891,667 additional shares of common stock. The net proceeds from the sale of shares, after deducting underwriting discounts, commissions and other estimated offering expenses, will be approximately $112 million.
J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the offering. BMO Capital Markets Corp. acted as lead manager and William Blair & Company, L.L.C. acted as co-manager.
A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on June 17, 2014. The offering was made only by means of a written prospectus forming part of the effective registration statement. A final prospectus for the offering, may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: (866) 803-0204; or Credit Suisse Securities (USA) LLC, One Madison Avenue, New York, NY 10010, Telephone: (800) 221-1037, Email: email@example.com. A copy of the final prospectus is also available on the Securities and Exchange Commission’s website at http://www.sec.gov under the registrant’s name, “ZS Pharma, Inc.”
This press release does not constitute an offer to sell or a solicitation of an offer to buy, the securities described above, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ZS Pharma
ZS Pharma is a specialty pharmaceutical company based in Coppell, Texas. ZS Pharma’s lead therapeutic candidate, ZS-9, is an investigational treatment for hyperkalemia that is being evaluated in late-stage clinical trials to demonstrate its ability to safely and effectively remove excess potassium from the blood and maintain normal potassium levels. ZS Pharma is also pursuing the discovery of additional drug candidates that utilize its novel selective ion-trap technology for the treatment of kidney and liver diseases.